Histoire Symptômes Prévalence Épidémiologie Raynauds? Traitement Références

Title


^ "Raynaud disease" at Dorland's Medical Dictionary

^ Anderson ME, Moore TL, Lunt M, Herrick AL (March 2007). "The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon". Rheumatology 46 (3): 533–8. doi:10.1093/rheumatology/kel330. PMID 17018538.

^ Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (June 2006). "Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance". Arthritis and Rheumatism 54 (6): 1974–81. doi:10.1002/art.21912. PMID 16732585.

^ Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. p. 542. ISBN 0-7216-0187-1.

^ Holmen OL, Backe B (2009). "An underdiagnosed cause of nipple pain presented on a camera phone". BMJ 339: b2553. doi:10.1136/bmj.b2553.

^ Anderson JE, Held N, Wright K (April 2004). "Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding". Pediatrics 113 (4): e360–4. doi:10.1542/peds.113.4.e360. PMID 15060268.

^ Pistorius MA, Planchon B, Schott JJ, Lemarec H (February 2006). "[Heredity and genetic aspects of Raynaud's disease"] (in French). Journal Des Maladies Vasculaires 31 (1): 10–5. PMID 16609626.

^ Gayraud M (January 2007). "Raynaud's phenomenon". Joint, Bone, Spine 74 (1): e1–8. doi:10.1016/j.jbspin.2006.07.002. PMID 17218139.

^ Berlin AL, Pehr K (March 2004). "Coexistence of erythromelalgia and Raynaud's phenomenon". Journal of the American Academy of Dermatology 50 (3): 456–60. doi:10.1016/S0190-9622(03)02121-2. PMID 14988692.

^ Priollet P (October 1998). "[Raynaud's phenomena: diagnostic and treatment study]" (in French). La Revue Du Praticien 48 (15): 1659–64. PMID 9814067.

^ Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M (April 1981). "Nifedipine and Raynaud's phenomenon". Annals of Internal Medicine 94 (4 pt 1): 546. PMID 7212523.

^ Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M (April 1982). "[Controlled study of nifedipine in the treatment of Raynaud's phenomenon]" (in French). Revue Du Rhumatisme et Des Maladies Ostéo-articulaires 49 (5): 337–43. PMID 6285445.

^ Smith CR, Rodeheffer RJ (January 1985). "Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers". The American Journal of Cardiology 55 (3): 154B–157B. doi:10.1016/0002-9149(85)90625-3. PMID 3881908.

^ Pancera P, Sansone S, Secchi S, Covi G, Lechi A (November 1997). "The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon". Journal of Internal Medicine 242 (5): 373–6. doi:10.1046/j.1365-2796.1997.00219.x. PMID 9408065.

^ Dziadzio M, Denton CP, Smith R, et al. (December 1999). "Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial". Arthritis and Rheumatism 42 (12): 2646–55. doi:10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T. PMID 10616013.

^ Waldo R (March 1979). "Prazosin relieves Raynaud's vasospasm". JAMA 241 (10): 1037. doi:10.1001/jama.241.10.1037. PMID 762741.

^ Fries R, Shariat K, von Wilmowsky H, Böhm M (November 2005). "Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy". Circulation 112 (19): 2980–5. doi:10.1161/CIRCULATIONAHA.104.523324 (inactive 2010-02-15). PMID 16275885.

^ Wang WH, Lai CS, Chang KP, et al. (October 2006). "Peripheral sympathectomy for Raynaud's phenomenon: a salvage procedure". The Kaohsiung Journal of Medical Sciences 22 (10): 491–9. doi:10.1016/S1607-551X(09)70343-2. PMID 17098681.

^ Neumeister MW, Chambers CB, Herron MS, et al. (July 2009). "Botox therapy for ischemic digits". Plastic and Reconstructive Surgery 124 (1): 191–201. doi:10.1097/PRS.0b013e3181a80576. PMID 19568080.

^ Van Beek AL, Lim PK, Gear AJ, Pritzker MR (January 2007). "Management of vasospastic disorders with botulinum toxin A". Plastic and Reconstructive Surgery 119 (1): 217–26. doi:10.1097/01.prs.0000244860.00674.57. PMID 17255677.

^ Muir AH, Robb R, McLaren M, Daly F, Belch JJ (2002). "The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial". Vascular Medicine 7 (4): 265–7. doi:10.1191/1358863x02vm455oa. PMID 12710841.

^ Tucker AT, Pearson RM, Cooke ED, Benjamin N (November 1999). "Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial". Lancet 354 (9191): 1670–5. doi:10.1016/S0140-6736(99)04095-7. PMID 10568568.

^ Karavidas MK, Tsai PS, Yucha C, McGrady A, Lehrer PM (September 2006). "Thermal biofeedback for primary Raynaud's phenomenon: a review of the literature". Applied Psychophysiology and Biofeedback 31 (3): 203–16. doi:10.1007/s10484-006-9018-2. PMID 17016765.

^ DiGiacomo RA, Kremer JM, Shah DM (February 1989). "Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study". The American Journal of Medicine 86 (2): 158–64. doi:10.1016/0002-9343(89)90261-1. PMID 2536517.


Lien parrainage

Lien parrainage


Lien parrainage


© Raynauds.biz